EVALUATION OF 2'-DCF IN RECOMBINANT LEUKOCYTE IFN ALPHA IN HAIRY CELL LEUKEMIA

毛细胞白血病重组白细胞 IFN α 中 2-DCF 的评估

• 批准号: 3963347
• 负责人: R G STEIS
• 金额: --
• 依托单位: DIVISION OF CANCER TREATMENT
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3963347
• 关键词: adenosine deaminase; combination chemotherapy; drug adverse effect; hairy cell leukemia; human subject; human therapy evaluation; human tissue; immunosuppressive; interferons; neoplasm /cancer chemotherapy; neoplasm /cancer immunotherapy

Hairy cell leukemia has recently been found to be responsive to recombinant alpha interferon. This drug is capable of inducing complete responses in patients with this disease, but the early results suggest that this drug is incapable of curing the disease or of making all patients respond continuously. As a result, we are currently investigating the use of combining recombinant alpha interferon with 2'-deoxycoformycin, another drug recently found to have significant activity in hairy cell leukemia. This combination approach appears to be particularly attractive since small numbers of patients resistant to alpha interferon have responded to deoxycoformycin. Although very active in this disease, deoxycoformycin has significant toxicity as well. We are administering deoxycoformycin in low doses weekly for three consecutive weeks followed by one month of daily recombinant alpha interferon. By this mechanism we hope to avoid the cumulative toxicity with deoxycoformycin and yet still be able to take advantage of its rapid antileukemic effect. By interrupting dCF therapy, we hope to limit the toxicity related to this drug. However, while patients are recovering from dCF-related toxicity, continuing antileukemic therapy in the form of alpha interferon will be continued. In this way, we hope to take advantage of the beneficial aspects of deoxycoformycin and interferon while at the same time minimumizing the negative aspects of each drug. So far eight patients have been admitted to this study, and as expected all patients are showing early signs of response. Significant myelosuppression due to deoxycoformycin has been observed in all patients. Two patients of the initial eight have been admitted to receive antibotics for granulocytopenia and fever. It is too early to comment on the extent or duration of response.

毛细胞白血病最近被发现对重组 α干扰素 这种药物能够诱导完全反应， 这种疾病的患者，但早期的结果表明，这种药物是 无法治愈疾病或使所有患者都有反应 不断地。 因此，我们目前正在研究使用 将重组α干扰素与2 '-脱氧共形霉素组合， 最近发现一种药物对毛细胞白血病有显著的作用。 这种组合方法似乎特别有吸引力，因为小 许多对α干扰素有抵抗力的患者对 去氧辅霉素。 尽管脱氧共形霉素在这种疾病中非常活跃， 毒性也很大。 我们在低剂量下使用脱氧共形霉素 连续三周每周一次给药，随后一个月每日一次给药 重组α干扰素 通过这种机制，我们希望避免 累积毒性与脱氧coformycin，但仍然能够采取 其快速抗白血病作用的优点。 通过中断dCF治疗， 我们希望限制这种药物的毒性。 虽然 患者正在从dCF相关毒性中恢复，继续抗白血病治疗 将继续α干扰素形式的治疗。 这样我们 希望利用脱氧共形霉素的有益方面， 干扰素，同时最大限度地减少每种干扰素的负面影响， 药 到目前为止，已有8名患者接受了这项研究，正如预期的那样， 病人已经显示出早期的反应迹象。 显著的骨髓抑制 在所有患者中均观察到脱氧共形霉素所致的 两名患者 最初的八个人已经被允许接受抗生素治疗， 粒细胞减少症和发热。 现在评论其程度还为时过早， 反应的持续时间。